Unsustainably high prescription drug prices threaten Americans’ access to care. In 2023, 28 percent of adults reported difficulty affording their prescription drugs, and 3 in 10 reported not taking their medication as prescribed due to cost. In response, state policymakers are exploring a range of options to protect patients from high out-of-pocket drug costs.
Join the Center for American Progress on June 20, 2024, from 1:00 to 2:00 p.m. EDT to learn more about state reforms to improve prescription drug affordability, including through establishing prescription drug affordability boards, setting out-of-pocket cost caps, and entering into bulk purchasing agreements.
- Dr. Andrew York, executive director of the Maryland Prescription Drug Affordability Board, will provide an overview of the board’s cost review study process, including the recent selection of six drugs for cost review.
- Shabnam Salih, director of the New Jersey Governor’s Office of Health Care Affordability and Transparency, will discuss enacted legislation (S1614 and S1615) that capped monthly out-of-pocket costs for insulin, EpiPens, and asthma inhalers as well as established a Drug Affordability Council.
- Dr. Beth Slamowitz, senior policy adviser on pharmacy at the Nevada Department of Health and Human Services, will discuss Nevada’s experience as a member of ArrayRx (previously Northwest Prescription Drug Consortium) and the impact of bulk purchasing on prescription drug affordability.